Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05613088 2026-04-30

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

106 enrolled 23 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02867956 2026-03-10

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Phase 2 Completed

35 enrolled

Gynecologic

Ovarian Neoplasms

NCT04089189 2026-01-28

SABRINA

Phase 2 Completed

93 enrolled

Gynecologic

Ovarian Neoplasms

NCT05041257 2026-01-09

PICCOLO

Phase 2 Completed

79 enrolled 14 charts

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02001272 2025-12-19

EWOC-1

Phase 2 Completed

120 enrolled

Gynecologic

Ovarian Neoplasms

NCT05001347 2025-12-16

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2 Completed

25 enrolled 11 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05348356 2025-12-15

Nirogacestat in Ovarian Granulosa Cell Tumors

Phase 2 Completed

53 enrolled

Gynecologic

Granulosa cell tumor of the ovary, Ovarian Neoplasms

NCT04339140 2025-12-11

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Phase 2 Completed

5 enrolled 4 charts

Gynecologic

Ovarian Neoplasms

NCT03188432 2025-10-21

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

50 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03776812 2025-10-07

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

178 enrolled 21 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05446870 2025-10-01

MK-4830-002

Phase 2 Completed

160 enrolled 19 charts

Gynecologic

Ovarian Neoplasms

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03275506 2025-09-11

NEOPEMBROV

Phase 2 Completed

91 enrolled

Gynecologic

Ovarian Neoplasms

NCT02498600 2025-08-29

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

100 enrolled 13 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05815862 2025-08-29

Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

Phase 2 Completed

29 enrolled

Gynecologic

Ovarian Neoplasms

NCT01767675 2025-08-27

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

99 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

613 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03395080 2025-08-01

P204

Phase 2 Completed

111 enrolled 22 charts

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2 Completed

105 enrolled 29 charts

Gynecologic

Ovarian Neoplasms

NCT03267589 2025-07-29

Trial in Patients With Relapsed Ovarian Cancer

Phase 2 Completed

25 enrolled

Gynecologic

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Gynecologic

Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01309230 2025-06-08

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

Phase 2 Completed

39 enrolled 13 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

108 enrolled

Gynecologic

Ovarian Neoplasms

NCT03268382 2025-03-17

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Phase 2 Completed

36 enrolled 13 charts

Gynecologic

Ovarian Neoplasms, Recurrence

NCT04870177 2025-02-28

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Phase 2 Completed

53 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04517357 2025-02-24

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Phase 2 Completed

100 enrolled

Gynecologic

Ovarian Neoplasms

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT03532139 2025-01-23

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Phase 2 Completed

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Gynecologic

Ovarian Neoplasms

NCT00170573 2024-12-16

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Phase 2 Completed

77 enrolled 9 charts

Gynecologic

Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

13 enrolled 14 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03648489 2024-09-20

DICE

Phase 2 Completed

134 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05322889 2024-08-28

PrevTel

Phase 2 Completed

35 enrolled

BreastGynecologic

Breast Neoplasms, Neuralgia, Ovarian Neoplasms

NCT01696032 2024-08-27

SGI-110

Phase 2 Completed

120 enrolled 22 charts

Gynecologic

Ovarian Neoplasms

NCT03602586 2024-07-26

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Phase 2 Completed

14 enrolled 12 charts

Gynecologic

Ovarian Neoplasms

NCT03759600 2024-07-16

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Phase 2 Completed

20 enrolled 42 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Phase 2 Completed

84 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT03759587 2024-06-07

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Phase 2 Completed

19 enrolled 39 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2 Completed

730 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT00445965 2024-04-04

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Phase 2 Completed

78 enrolled 11 charts

CNSDermatologicGynecologicOther solid neoplasmSarcomaThoracic

Familial ependymoma, Uveal Melanoma, Astrocytoma, Brain Neoplasms, Chondrosarcoma, Ependymoma, Glioblastoma, Glioma, Lung Neoplasms, Medulloblastoma, Melanoma, Neoplasm Metastasis, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Glioma, Subependymal, Gliosarcoma, Rhabdoid Tumor, Optic Nerve Glioma, Small Cell Lung Carcinoma, Desmoplastic Small Round Cell Tumor

NCT01001910 2024-02-28

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

22 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03012620 2024-02-28

AcSé

Phase 2 Completed

334 enrolled

CNSEndocrineGynecologicHead & NeckLymphoidSarcoma

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

NCT02766582 2024-02-26

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Phase 2 Completed

29 enrolled 9 charts

Gynecologic

Ovarian Neoplasms

NCT02901899 2024-02-20

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

45 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

PROMPT

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

LEAP-005

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

SABRINA

PICCOLO

EWOC-1

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Nirogacestat in Ovarian Granulosa Cell Tumors

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MK-4830-002

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NEOPEMBROV

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

KEYVIBE-005

P204

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Trial in Patients With Relapsed Ovarian Cancer

OPAL

EUDARIO

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

BRIGHT

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Study of AK112 in the Treatment of Advanced Gynecological Tumors

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

BAROCCO

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

DICE

PrevTel

SGI-110

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

AcSé

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer